3-Bromo-4-chloroaniline can be used as an intermediate in pharmaceutical synthesis, such as the preparation of Vismodegib, the trade name is Erivedge, the chemical name is 2-chloro-N-(4-chloro-3 -(Pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, developed by Curis, Genentech and Evotec in cooperation, was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2012 ) marketing approval as a small molecule targeted inhibitor of the Hedgehog pathway for the treatment of basal cell carcinoma.
